某市蒙古族与汉族肺腺癌EGFR基因突变的分析

摘要

目的：研究内蒙古包头市蒙古族肺腺癌EGFR突变与汉族肺腺癌EGFR突变表达是否存在差异。方法收集临床肺腺癌患者石蜡包埋组织标本108例，包括53例蒙古族和55例汉族肺腺癌的样本，采用ARMS（amplification refractory mutation system, ARMS）PCR扩增方法检测非小细胞肺癌EGFR基因外显子18、19、20及21的突变，χ2析对比内蒙古地区蒙古族和汉族肺腺癌EGFR基因突变差异。结果108例肺腺癌患者中有46例EGFR基因突变，总突变率为42.59%，其中蒙古族突变22例，突变率为41.51%，汉族突变24例，突变率为43.64%，内蒙古包头市蒙古族肺腺癌EGFR突变率与汉族肺腺癌EGFR突变率比较无明显差异（P<0.001），突变以外显子19核苷酸缺失起始位2235为主要突变点。结论内蒙古包头市蒙古族中肺腺癌EGFR基因突变率为41.51%，汉族中EGFR基因突变率为43.64%，内蒙古包头市蒙古族肺腺癌EGFR突变率与汉族肺腺癌EGFR突变率比较无明显差异，都适宜靶向药物治疗。%ObjectiveTo investigate ethnic difference and correlation of EGFR of non-small cell lung cancer in the Mongolian and Han patients in Baotou city of Inner Mongolia Mongolian.MethodsCollect the clinical patients with adenocarcinoma of the lung parafifn-embedded tissue specimens from 108 patients, including 53 cases in Inner Mongolia baotou city Mongolia group and 55 cases of Han lung adenocarcinoma samples, using ARMS (ampliifcation refractory mutation system, ARMS) PCR ampliifcation method for detection of non-small cell lung cancer EGFR gene exon 18, 19, 20 and 21 differences between the mutant gene mutation, Mongolia and Han nationality in lung adenocarcinoma EGFR,χ2 comparative analysis of Baotou city of Inner Mongolia Results108 cases of patients with lung adenocarcinoma in 46 cases of EGFR gene mutation, the total mutation rate was 42.59%, of which Mongolia in 22 cases, the mutation rate was 41.51%, the Han nationality in 24 cases, the mutation rate was 43.64%, the Baotou city of Inner Mongolia of Mongolia group of lung adenocarcinoma EGFR mutation rate and the Han nationality mutation rate of EGFR in lung adenocarcinoma than no signiifcant difference (P<0.001), mutation exon 19 deletion of nucleotides initiation 2235 as main point mutations.ConclusionThe gene of Mongolia family in lung adenocarcinoma EGFR Inner Mongolia region mutation rate was 41.51%, the Han EGFR gene mutation rate was 43.64%, the Inner Mongolia baotou city of Mongolia group of lung adenocarcinoma EGFR mutation rate and mutation rate in lung adenocarcinoma EGFR were no signiifcant difference, are suitable for targeted drug therapy.